Graph for Max Amplitude/Length at G_y = 0. by Muhammad Hammad Bucha (21736111)

“…The smoothest cylinder (K_s/D = ) produced the highest power (52.325 µW), while the roughest (K_s/D = ) resulted in a 6.26% decrease in power (36.4 µW), along with reductions of 4.5% in flapping frequency and 20% in amplitude. …”

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P_i-induced VSMCs. …”

Comparison of W_max (A), the changes in V_E (B), and W_VT (C) among the three oxygen conditions. by Kazufumi Hisamoto (21416905)

(A) Rapid light curves, (B) maximum electron transport rates (ETR_max) and (C) minimum saturating irradiances (E_k) derived from the model fitted according to P... by Malte Ostendarp (13217973)

(A) Rapid light curves, (B) maximum electron transport rates (ETR_max) and (C) minimum saturating irradiances (E_k) derived from the model fitted according to P... by Malte Ostendarp (13217973)

Initial structure and optimized structure Battery <i>T</i>_<i>max</i> and <i>T</i>_<i>min</i>. by Xueyong Pan (20390363)

Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P_i‐induced VSMCs. …”

(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. by Long Li (6555)

Percentage of exhale flux penetrating through the mask fabric for different values of <i>c</i>_<i>k</i>; a–c and d–f decreasing porosity for outward and inward protection model respectively; <i>k</i>_<i>L</i> is head loss coefficient for inward protection model. by Akshay Anand (118579)

MigC interacts with and decreases the activity of MurD. by Jeanette M. Critchlow (21553796)

General procedure for the synthesis of A and A-c1. by Xueqin lu (22250795)

The affected dogs have a complete loss of IP₃R3 and reduced IP₃R1 and IP₃R2 protein levels. by Marjo K. Hytönen (8522271)

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

ST2-104 decreases the Aβ_25-35-mediated increase in intracellular Ca²⁺. by Yingshi Ji (9013004)

Distribution of final population size (A) and mean change in mean MSI over time (B) over 100 simulations for each parameter set shown in Table 3 in the absence of weevils (left) an... by Alexandra M. Campbell (3284094)

Acute starvation decreases the Brp::rGFP heterogeneity level among γcompartments. by Hongyang Wu (8856740)

Activation, inactivation, and deactivation kinetics differ between Ca_V3.3 WT and variants as well as among the variants. by Yousra El Ghaleb (22075892)

Design, Synthesis, and Biological Evaluation of [1,2,5]Oxadiazolo[3,4‑<i>b</i>]pyridin-7-ol as Mitochondrial Uncouplers for the Treatment of Obesity and Metabolic Dysfunction-Assoc... by Mary A. Foutz (20361830)

Subjects:

Contribution of the through-mask leakages from the cavity and channel network distributed along the periphery of the mask; a–c and d–f are decreasing porosity <i>c</i>_<i>k</i> = 100,500,1000 (<i>kg</i>/<i>m</i>² <i>s</i>) for outward protection (with nose clips) and inward protection model, respectively; the <i>k</i>_<i>L</i> for inward protection model is 0.5. by Akshay Anand (118579)

“…<p>Contribution of the through-mask leakages from the cavity and channel network distributed along the periphery of the mask; a–c and d–f are decreasing porosity <i>c</i>_<i>k</i> = 100,500,1000 (<i>kg</i>/<i>m</i>² <i>s</i>) for outward protection (with nose clips) and inward protection model, respectively; the <i>k</i>_<i>L</i> for inward protection model is 0.5.…”

Male flies with a mixed background have not responded to high temperature-mediated body fat loss. by Tucker Hopkins (20790529)